Robert J. Motzer, MD, provides an overview of the CLEAR trial investigating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Renal Cell Carcinoma Treatment Updates from ASCO 2023 and KCRS 2023
An expert medical oncologist reviews recent data updates on lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Continuing discussion on advanced renal cell carcinoma, Robert J. Motzer, MD, reviews recent clinical trial data presented at ASCO 2023 and KCRS 2023.
Robert J. Motzer, MD, provides insights on factors that influence treatment decisions for patients with clear cell renal cell carcinoma.
A comprehensive review of second-line treatment options for patients with clear cell renal cell carcinoma.
A key opinion leader in the field of renal cell carcinoma offers clinical insight on treatment sequencing strategies.
Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.
Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.
Clinical insights from a leader in kidney cancer research on the differences between clear cell and non–clear cell renal cell carcinoma.
A medical oncologist reviews recent data updates from the 2023 ASCO Annual Meeting for non–clear cell renal cell carcinoma.
Robert J. Motzer, MD, concludes the program with insights on promising treatment options for patients with non–clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
